Company profile
Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Aleniglipron | phase1_2 | — | 3 | completed, unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06703021 | phase2 | completed | 2024-12-20 | 2026-01-12 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity |
| NCT06693843 | phase2 | completed | 2024-10-28 | 2025-10-24 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity |
| NCT07654374 | phase3 | recruiting | 2026-07-17 | 2028-09-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) |
| NCT05893043 | phase1 | completed | 2023-04-24 | 2023-06-28 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants |
| NCT06139055 | phase1 | unknown | 2023-10-02 | 2024-03-01 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants |
FDA applications (0)
No records yet.